Ibrutinib induces durable remissions in treatment-naive patients with CLL and 17p deletion and/or TP53 mutations.

ABSTRACT:

SUBMITTER: Sivina M 

PROVIDER: S-EPMC8832441 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature